Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Prices $8.0 Billion Debt Offering

Business Wire February 5, 2015

Merck (MRK) Q4 profit skyrockets soundly beating estimates

Canadian Press February 4, 2015

Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results

Business Wire February 4, 2015

Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

Business Wire February 3, 2015

Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate)

Business Wire January 26, 2015

Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist's 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020

Business Wire January 22, 2015

Merck Completes Tender Offer to Acquire Cubist

Business Wire January 21, 2015

Dana Holding Set to Join the S&P MidCap 400

PR Newswire January 20, 2015

Practice Fusion Announces Positive Results of Population Health Vaccine Initiative Conducted in Collaboration with Merck

PR Newswire January 14, 2015

Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

Business Wire January 13, 2015

Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference

Business Wire January 12, 2015

Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Business Wire January 9, 2015

Cleveland HeartLab snaps up cardio risk assessment technology

Stockhouse Editorial January 8, 2015

Theralase Anti-Cancer Technology Picks Up Steam

Accesswire January 6, 2015

Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4

Business Wire January 5, 2015

NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award

GlobeNewswire December 22, 2014

Merck Begins Tender Offer to Acquire Cubist

Business Wire December 19, 2014

Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

Business Wire December 18, 2014

CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST

PR Newswire December 12, 2014

Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health

Business Wire December 10, 2014